LB PHARMACEUTICALS INC (LBRX) Form 424B3 — Jun 10, 2026

$LBRXForm 424B3Filed Jun 10, 2026, 5:00 PM ET0001193125-26-266020Original filing

LB Pharmaceuticals Inc filed a prospectus supplement to its S-1 registration statement, incorporating a Form 8-K that discloses the resignation of Anna Eramo, M.D., as Chief Medical Officer effective June 15, 2026. Dr. Eramo is transitioning to a full-time advisor role through September 15, 2026, and will receive accelerated vesting of 66,143 stock options and prorated bonus payments under a separation agreement.

Key figures

Last stock price: $29.27
Unvested options vested: 66143

AI analysis

Red flags2 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.